Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Communications • Transportation, E-Commerce & Mechanical Systems
5 pending office actions • 5 clients • 5 examiners • 5 art units • 0 of 5 (0%) have an AI response strategy ready
KOHN & ASSOCIATES, PLLC operates in the Biotechnology & Pharmaceuticals technology area, where it has filed 722 career applications. The firm's resolved allowance rate is 67.1 percent, which measures the proportion of its cases that reach a grant. This history of 722 career applications provides the firm with a basis for its experience in navigating the patent office's requirements for life sciences inventions.
The firm's prosecution process involves an average of 4.52 office actions per allowance. This metric indicates the typical number of interactions between the firm and patent examiners before an application reaches an allowance. For a practitioner, this average of 4.52 office actions per allowance suggests a prosecution cycle that involves multiple responses to the patent office. Currently, the firm is managing 4 pending office actions within its Biotechnology & Pharmaceuticals practice.
The 67.1 percent allowance rate and the 4.52 office actions per allowance serve as data points for understanding the firm's prosecution history. The 4 pending office actions represent the firm's current workload, while the 722 career applications reflect its historical activity. These figures offer a data-grounded view of the firm's performance and its ongoing role in the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (20%) |
| §101 + other | 1 (20%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KEENAN, JAMES W | 1 | 66.8% | +24.1% |
| KINGDON, CATHY | 1 | 80.3% | +2.5% |
| LAM, ELIZA ANNE | 1 | 38.4% | +31.3% |
| DRISCOLL, LORA E BARNHART | 1 | 32.0% | +20.0% |
| JAIN, ANKUR | 1 | 74.9% | +5.9% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18855454 | STABILIZED FORMULA OF CROTOXIN | KINGDON, CATHY | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18939802 | SMART NUTRITION DOSING | LAM, ELIZA ANNE | 3d overdue |
| 18774363 | NANOEMULSION COMPOSITIONS OF TAXOID DRUGS, AND METHODS FOR THE USE THEREOF TO TARGET CANCER CELLS AND CANCER STEM CELLS | DRISCOLL, LORA E BARNHART | 27d |
| 19107413 | MOUNTABLE / DEMOUNTABLE / REMOUNTABLE INTERCHANGABLE EQUIPMENT SLED | KEENAN, JAMES W | — |
| 18653531 | SCREEN PROTECTOR WITH ENGRAVED IMAGE | JAIN, ANKUR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18939802 | SMART NUTRITION DOSING | LAM, ELIZA ANNE | 3d overdue |
| 18774363 | NANOEMULSION COMPOSITIONS OF TAXOID DRUGS, AND METHODS FOR THE USE THEREOF TO TARGET CANCER CELLS AND CANCER STEM CELLS | DRISCOLL, LORA E BARNHART | 27d |
| 19107413 | MOUNTABLE / DEMOUNTABLE / REMOUNTABLE INTERCHANGABLE EQUIPMENT SLED | KEENAN, JAMES W | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Hurst Engineered Advanced Technologies (Heat) LLC | 1 |
| Celtic Biotech Ltd. | 1 |
| OptimDosing LLC | 1 |
| Northeastern University | 1 |
| Screen Skinz, Inc. | 1 |
| Art Unit | Apps |
|---|---|
| 3655 | 1 |
| 1653 | 1 |
| 3681 | 1 |
| 3991 | 1 |
| 2649 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19107413 | MOUNTABLE / DEMOUNTABLE / REMOUNTABLE INTERCHANGABLE EQUIPMENT SLED | Hurst Engineered Advanced Technologies (Heat) LLC | KEENAN, JAMES W | 3655 | §103§112 | Non-Final OA | — | Pending | Feb 27, 2025 |
| 18855454 | STABILIZED FORMULA OF CROTOXIN | Celtic Biotech Ltd. | KINGDON, CATHY | 1653 | §103§112DP | Non-Final OA | — | Pending | Dec 31, 2024 |
| 18939802 | SMART NUTRITION DOSING | Optimdosing LLC | LAM, ELIZA ANNE | 3681 | §101§103Other | Final Rejection | 3d overdue | Pending | Nov 07, 2024 |
| 18774363 | NANOEMULSION COMPOSITIONS OF TAXOID DRUGS, AND METHODS FOR THE USE THEREOF TO TARGET CANCER CELLS AND CANCER STEM CELLS | Northeastern University | DRISCOLL, LORA E BARNHART | 3991 | §101 | Final Rejection | 27d | Pending | Jul 16, 2024 |
| 18653531 | SCREEN PROTECTOR WITH ENGRAVED IMAGE | Screen Skinz, Inc. | JAIN, ANKUR | 2649 | §103§112 | Non-Final OA | — | Pending | May 02, 2024 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial